Plasmology4

Plasmology4 is developing a novel medical device platform based on non-thermal plasma (Plaz4 Technology) for therapeutic applications, initially targeting infected and chronic wounds. Its lead product, the Plaz4 1000 system, has received FDA Breakthrough Device designation and is aiming for regulatory approval in 2027. The company boasts a strong IP position with 48 issued patents and is led by a management team with deep experience in medical devices and biomedical research. Plasmology4 represents a potential paradigm shift in treating antimicrobial-resistant infections without drugs.

Plaz4 Technology, a proprietary and advanced form of non-thermal plasma (ionized gas at near-room temperature) that generates reactive species for therapeutic applications such as killing pathogens and stimulating tissue healing.

Competition includes established advanced wound care companies (e.g., 3M, Smith & Nephew, Mölnlycke) offering antimicrobial dressings and negative pressure therapies, as well as emerging biotechnologies like phage therapy or novel antimicrobials. Plasmology4's primary differentiation is its physics-based, drug-free platform offering simultaneous disinfection and healing stimulation.